公司诉讼案件 - Organon公司因涉嫌违反1934年证券交易法被提起集体诉讼 案件编号为Hauser v Organon & Co No 25-cv-05322 [1] - 诉讼指控公司高管在股息分配优先级和债务削减策略方面存在虚假或误导性陈述 导致季度股息大幅减少70% [4] - 2025年5月1日公司宣布将季度股息从每股0 28美元降至0 02美元 股价随即下跌27% [5] 公司业务 - Organon主要从事处方药和医疗器械的研发与销售 [3] - 公司在收购Dermavant Sciences Ltd后调整资本配置策略 将债务削减作为优先事项 [4] 诉讼程序 - 符合资格的投资者可在2025年7月22日前申请作为首席原告 [2] - 首席原告将代表全体集体诉讼成员主导案件进程 并有权选择代理律所 [6] 代理律所信息 - Robbins Geller律所在证券集体诉讼领域具有领先地位 过去五年有四年在ISS排名中位列第一 [7] - 该律所2024年为投资者追回超过25亿美元赔偿 创下过72亿美元的历史最高赔偿纪录 [7]

PHILADELPHIA, June 05, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) on behalf of purchasers of Organon securities between October 31, 2024 through April 30, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Organon securities during the Class Period may, no later than JULY 22, 2025, seek to be appointed as a lead plaintiff representa ...

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Organon investors who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/organon-co-lawsuit-submission-for ...

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material informat ...

诉讼案件 - 针对Organon公司的证券集体诉讼已提交 代表在2024年10月31日至2025年4月30日期间购买公司证券的投资者 [1] - 投资者需在2025年7月22日前申请成为首席原告代表 [2] 公司背景 - Organon总部位于新泽西州泽西市 是一家专注于女性健康的医疗保健公司 [2] - 2024年10月以12亿美元收购专注于皮肤病治疗的生物制药公司Dermavant [2] 诉讼指控 - 尽管Dermavant收购增加了债务 公司仍向投资者保证将维持股息 并将其描述为"第一资本分配优先事项" [3] - 2025年5月1日 公司将股息从每股0.28美元大幅下调至0.02美元 [3] - 管理层解释称"重新设定了资本分配优先级以加速去杠杆化" 并表示"目前向股东返还资本不是优先事项" [3] 市场反应 - 股息下调公告导致股价从2025年4月30日收盘价12.93美元下跌3.48美元至9.45美元 跌幅约27% [3] 法律程序 - 首席原告是代表所有集体诉讼成员指导诉讼的代表方 通常是具有最大财务利益的投资者或小组 [4] - 首席原告选择律师代表原告和集体 这些律师经法院批准后成为首席或集体律师 [4]

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/organon-co-loss-submission-form/?id=150969&from=3 CLASS PERIOD: October 31, 2024 to Apri ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Organon To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Organon between October 31, 2024 and April 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 4, 2025 /PRNewswire/ ...

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

集体诉讼事件 - 投资者针对Organon & Co在2024年10月31日至2025年4月30日期间证券交易行为提起集体诉讼 [1] - 公司为全球医疗保健企业 核心业务聚焦女性全生命周期健康管理 [1] 指控内容 - 公司被指控在债务削减策略上误导投资者 宣称季度分红是"资本分配第一优先级" 但实际隐瞒收购Dermavant后债务削减的高优先级 [2][3] - 真相披露后 季度股息从每股0.28美元骤降至0.02美元 降幅达70% [3][4] 市场反应 - 2025年5月1日财报公布后 公司股价从12.93美元/股暴跌至9.45美元/股 单日跌幅超27% [4] 诉讼程序 - 符合条件的投资者可申请成为首席原告 无需参与诉讼流程也可获得赔偿 [5] - 律所采用风险代理收费模式 投资者无需预付费用 [6]

公司诉讼事件 - Organon面临证券集体诉讼 指控其在2024年10月31日至2025年4月30日期间存在虚假陈述 [1] - 诉讼涉及公司收购Dermavant后改变资本分配优先级 未兑现维持股息的承诺 [3] - 2025年5月1日公司宣布将每股股息从0.28美元大幅削减至0.02美元 导致股价单日暴跌27%至9.45美元/股 [4] 公司业务动态 - Organon总部位于新泽西州 专注于女性健康领域 [2] - 2024年10月以12亿美元收购皮肤病生物制药公司Dermavant [2] - 管理层解释资本分配转向优先降债 股东回报成为次要目标 [4] 投资者法律程序 - 投资者可在2025年7月22日前申请成为首席原告代表 [2] - 首席原告需满足最大财务利益及典型性要求 可自主选择律师团队 [5] - 律师事务所Berger Montague在证券集体诉讼领域有50年经验 在全美多地设有办公室 [6]